Chembio Diagnostics, Inc. CEMI was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 265.6% in the past one-month time frame.
The stock gained after the company received the Emergency Use Authorization for its DPP COVID-19 System, which is a serological point-of-care test and analyzer.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Chembio Diagnostics, Inc. Price
Chembio Diagnostics, Inc. price | Chembio Diagnostics, Inc. Quote
Chembio currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked stock in the Medical - Products industry is Nephros Inc. NEPH, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Chembio Diagnostics, Inc. (CEMI) : Free Stock Analysis Report
Nephros Inc. (NEPH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research